Regentis Biomaterials Ltd. (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC, the company’s regenerative treatment for articular cartilage injuries. The allowance expands the company’s global intellectual property portfolio as it advances GelrinC commercialization in Europe, continues enrollment in its pivotal U.S. clinical trial and evaluates expansion into additional international markets.
The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable liquid formulations. According to the company, the technology improves manufacturing efficiency, increases production yield, simplifies manufacturing and enhances scalability for commercial production. This development is significant because it addresses key challenges in the production of hydrogel-based therapies, potentially lowering costs and improving access for patients.
Regentis said the patent also strengthens its position in Japan, one of the world’s largest cartilage repair markets, where demand is expected to grow as the population ages and the prevalence of knee osteoarthritis increases. The aging demographic in Japan is driving a higher incidence of knee osteoarthritis, a condition that often leads to cartilage damage requiring surgical intervention. GelrinC, a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allows surrounding cells to regenerate cartilage in a controlled and synchronous process. This addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. alone, where no off-the-shelf treatment is currently available.
The implications of this patent allowance are multifaceted. For Regentis, it provides a competitive advantage in Japan, a market where intellectual property protection is critical for commercial success. For patients, the technology behind GelrinC offers a potential alternative to existing treatments that often involve harvesting healthy cartilage or using cells grown in a lab. The manufacturing process, free of organic solvents, also aligns with growing regulatory and consumer preferences for greener, safer production methods.
For the orthopedic industry, the patent reinforces the shift toward regenerative medicine solutions that aim to restore damaged tissue rather than replace it. As Regentis moves closer to commercialization in Europe and progresses its U.S. pivotal trial, the Japan patent adds a layer of security for investors and partners. The company’s focus on scalability suggests that if GelrinC receives regulatory approvals, it could be produced in sufficient quantities to meet global demand.
The full press release is available at https://ibn.fm/w7h5A. For more information about Regentis Biomaterials, visit the company’s newsroom at https://ibn.fm/RGNT.
